Loading...
•
Sep 30, 2020
Scorpius Holdings Q3 2020 Earnings Report
Heat Biologics reported financial results for Q3 2020, highlighting progress in oncology and COVID-19 vaccine programs and maintaining a solid balance sheet.
Key Takeaways
Heat Biologics reported a net loss of $8.9 million, or $0.06 per share, and grant revenue of $0.8 million for the third quarter of 2020. The company had $117.3 million in cash and short-term investments as of September 30, 2020, and is advancing its oncology and COVID-19 vaccine programs.
Recognized $0.8 million of grant revenue for qualified expenditures under the CPRIT and NIH grants.
Research and development expenses were $3.2 million.
General and administrative expense was $6.6 million.
Net loss attributable to Heat Biologics was approximately $8.9 million, or ($0.06) per basic and diluted share.
Forward Guidance
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events.
Positive Outlook
- PTX-35 being the potential first-in-class T- cell costimulatory antibody
- The expected enrollment of the Phase 1 PTX-35 study
- The potential of Heat’s COVID-19 vaccine to be used as either a standalone vaccine or in combination with other antibody-focused vaccine approaches to enhance prophylactic protection
- The combination of Heat’s gp96 platform in a single therapy holding enormous promise in the prevention and treatment of cancer and infectious diseases, such as COVID-19
- Heat’s capital providing a significant runway to achieve a number of important clinical milestones that will drive value for shareholders in the months and years ahead
Challenges Ahead
- The ability of Heat's vaccine platform to provide protection against COVID-19
- The ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...